388 related articles for article (PubMed ID: 33215345)
21. The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated With Radiotherapy and Chemotherapeutic Agents.
Kurdi M; Shafique Butt N; Baeesa S; Alghamdi B; Maghrabi Y; Bardeesi A; Saeedi R; Al-Sinani T; Alghanmi N; Bari MO; Samkari A; Lary AI
Pathol Oncol Res; 2021; 27():1609778. PubMed ID: 34257620
[TBL] [Abstract][Full Text] [Related]
22. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
23. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
[TBL] [Abstract][Full Text] [Related]
24. Surgery for Glioblastoma in Light of Molecular Markers: Impact of Resection and MGMT Promoter Methylation in Newly Diagnosed IDH-1 Wild-Type Glioblastomas.
Gessler F; Bernstock JD; Braczynski A; Lescher S; Baumgarten P; Harter PN; Mittelbronn M; Wu T; Seifert V; Senft C
Neurosurgery; 2019 Jan; 84(1):190-197. PubMed ID: 29617848
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
[TBL] [Abstract][Full Text] [Related]
26. Arterial spin labeling perfusion-weighted imaging aids in prediction of molecular biomarkers and survival in glioblastomas.
Yoo RE; Yun TJ; Hwang I; Hong EK; Kang KM; Choi SH; Park CK; Won JK; Kim JH; Sohn CH
Eur Radiol; 2020 Feb; 30(2):1202-1211. PubMed ID: 31468161
[TBL] [Abstract][Full Text] [Related]
27. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
28. Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in
Felsberg J; Hentschel B; Kaulich K; Gramatzki D; Zacher A; Malzkorn B; Kamp M; Sabel M; Simon M; Westphal M; Schackert G; Tonn JC; Pietsch T; von Deimling A; Loeffler M; Reifenberger G; Weller M;
Clin Cancer Res; 2017 Nov; 23(22):6846-6855. PubMed ID: 28855349
[No Abstract] [Full Text] [Related]
29. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
[TBL] [Abstract][Full Text] [Related]
30. The treatment of glioblastomas: a systematic update on clinical Phase III trials.
Yin AA; Cheng JX; Zhang X; Liu BL
Crit Rev Oncol Hematol; 2013 Sep; 87(3):265-82. PubMed ID: 23453191
[TBL] [Abstract][Full Text] [Related]
31. Dose-intensified chemoradiation is associated with altered patterns of failure and favorable survival in patients with newly diagnosed glioblastoma.
Kim MM; Speers C; Li P; Schipper M; Junck L; Leung D; Orringer D; Heth J; Umemura Y; Spratt DE; Wahl DR; Cao Y; Lawrence TS; Tsien CI
J Neurooncol; 2019 Jun; 143(2):313-319. PubMed ID: 30977058
[TBL] [Abstract][Full Text] [Related]
32. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
Shu C; Wang Q; Yan X; Wang J
Cancer Med; 2018 Aug; 7(8):3704-3712. PubMed ID: 29984907
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.
Bosnyák E; Michelhaugh SK; Klinger NV; Kamson DO; Barger GR; Mittal S; Juhász C
Clin Nucl Med; 2017 May; 42(5):341-347. PubMed ID: 28195901
[TBL] [Abstract][Full Text] [Related]
34. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of cytoreductive surgery in the management of progressive glioblastoma in adults.
Patrick HH; Sherman JH; Elder JB; Olson JJ
J Neurooncol; 2022 Jun; 158(2):167-177. PubMed ID: 35246769
[TBL] [Abstract][Full Text] [Related]
35. Role of
Brandes AA; Franceschi E; Paccapelo A; Tallini G; De Biase D; Ghimenton C; Danieli D; Zunarelli E; Lanza G; Silini EM; Sturiale C; Volpin L; Servadei F; Talacchi A; Fioravanti A; Pia Foschini M; Bartolini S; Pession A; Ermani M
Oncologist; 2017 Apr; 22(4):432-437. PubMed ID: 28275120
[TBL] [Abstract][Full Text] [Related]
36. Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study.
Pinson H; Hallaert G; Van der Meulen J; Dedeurwaerdere F; Vanhauwaert D; Van den Broecke C; Van Dorpe J; Van Roost D; Kalala JP; Boterberg T
J Neurooncol; 2020 Jan; 146(1):55-62. PubMed ID: 31701343
[TBL] [Abstract][Full Text] [Related]
37. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
38. Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
Laprie A; Ken S; Filleron T; Lubrano V; Vieillevigne L; Tensaouti F; Catalaa I; Boetto S; Khalifa J; Attal J; Peyraga G; Gomez-Roca C; Uro-Coste E; Noel G; Truc G; Sunyach MP; Magné N; Charissoux M; Supiot S; Bernier V; Mounier M; Poublanc M; Fabre A; Delord JP; Cohen-Jonathan Moyal E
BMC Cancer; 2019 Feb; 19(1):167. PubMed ID: 30791889
[TBL] [Abstract][Full Text] [Related]
39. The Value of 5-Aminolevulinic Acid in Low-grade Gliomas and High-grade Gliomas Lacking Glioblastoma Imaging Features: An Analysis Based on Fluorescence, Magnetic Resonance Imaging, 18F-Fluoroethyl Tyrosine Positron Emission Tomography, and Tumor Molecular Factors.
Jaber M; Wölfer J; Ewelt C; Holling M; Hasselblatt M; Niederstadt T; Zoubi T; Weckesser M; Stummer W
Neurosurgery; 2016 Mar; 78(3):401-11; discussion 411. PubMed ID: 26366972
[TBL] [Abstract][Full Text] [Related]
40. Combined analysis of MGMT methylation and dynamic-susceptibility-contrast MRI for the distinction between early and pseudo-progression in glioblastoma patients.
Bani-Sadr A; Berner LP; Barritault M; Chamard L; Bidet CM; Eker OF; Hermier M; Guyotat J; Jouanneau E; Meyronet D; Gouttard S; D'Hombres A; Iziquierdo C; Honnorat J; Berthezène Y; Ducray F
Rev Neurol (Paris); 2019 Oct; 175(9):534-543. PubMed ID: 31208813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
